{"organizations": [], "uuid": "fc4178c0f3a7c00bb0422366689b97c75d9499cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biofrontera-receives-favorable-chm/brief-biofrontera-receives-favorable-chmp-assessment-for-ameluz-in-combination-with-daylight-photodynamic-therapy-idUSFWN1PO0P3", "country": "US", "domain_rank": 408, "title": "BRIEF-Biofrontera Receives Favorable CHMP Assessment For Ameluz In Combination With Daylight Photodynamic Therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.989, "site_type": "news", "published": "2018-01-29T19:26:00.000+02:00", "replies_count": 0, "uuid": "fc4178c0f3a7c00bb0422366689b97c75d9499cf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biofrontera-receives-favorable-chm/brief-biofrontera-receives-favorable-chmp-assessment-for-ameluz-in-combination-with-daylight-photodynamic-therapy-idUSFWN1PO0P3", "ord_in_thread": 0, "title": "BRIEF-Biofrontera Receives Favorable CHMP Assessment For Ameluz In Combination With Daylight Photodynamic Therapy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biofrontera ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - BIOFRONTERA AG:\n* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES FAVORABLE CHMP ASSESSMENT FOR AMELUZÂ® IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY\n* BASED ON POSITIVE OPINION, CO ANTICIPATES FORMAL APPROVAL BY EUROPEAN COMMISSION IN COMING WEEKS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T19:26:00.000+02:00", "crawled": "2018-01-30T18:59:43.005+02:00", "highlightTitle": ""}